2-[3-(4-tert-butyl-2-methoxy-benzoylamino)-phenyl]-pyrrolidine | 773832-11-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[3-(4-tert-butyl-2-methoxy-benzoylamino)-phenyl]-pyrrolidine
• 英文别名: (+/-)-4-tert-Butyl-2-methoxy-N-(3-pyrrolidin-2-yl-phenyl)-benzamide；4-tert-butyl-2-methoxy-N-(3-pyrrolidin-2-ylphenyl)benzamide
• CAS: 773832-11-4
• 化学式: C₂₂H₂₈N₂O₂
• 分子量: 352.477
• InChiKey: CZBQSIALJSXNLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (+/-)-2-[3-(4-tert-butyl-2-methoxy-benzoylamino)-phenyl]-1-(tert-butyloxycarbonyl)-pyrrolidine 以 甲醇 、 盐酸 为溶剂， 反应 18.0h， 以gave the title compound as a colourless solid (0.029 g)的产率得到2-[3-(4-tert-butyl-2-methoxy-benzoylamino)-phenyl]-pyrrolidine
  参考文献：
  名称：

  Substituted benzamide derivatives and pharmaceutical compositions containing them

  摘要：

  公式（I）的化合物及其药学上可接受的盐，其中G为亚甲基或乙烯基链；R1为氢、C1-6烷基O-；R2为氢、卤素、CN、N3、三氟甲基二氮杂环基、CF3、CF3O-、CF3S-、CF3CO-、C1-6烷基、C3-6环烷基、C3-6环烷基-C1-4烷基、C1-6烷基O-、C1-6烷基CO-、C3-6环烷基CO-、C3-6环烷基-C1-4-烷基CO-、苯基、苯氧基、苄氧基、苯甲酰基和取代苯甲酰基、苯基-C1-4烷基-、C1-6烷基SO2-、(C1-4烷基)2NSO2-或(C1-4烷基)NHSO2-；R3为氢、卤素、CN、N3、三氟甲基二氮杂环基、C1-6烷基O-、C1-6烷基S-、C1-6烷基、C3-6环烷基、C3-6环烷基-C1-4烷基、C1-6烯基、C1-6炔基、CF3CO-、C1-6烷基CO-、C3-6环烷基CO-、C3-6环烷基-C1-4烷基CO-、苯基、苯氧基、苄氧基、苯甲酰基、苯基-C1-4烷基-或-NR5R6，其中R5为氢或C1-4烷基；R6为氢、C1-4烷基、-CHO、-CO2C1-4烷基或-COC1-4烷基；R4为氢、C1-6烷基、C1-6烯基或C1-6炔基，可用于预防和治疗与蛛网膜下腔出血或神经休克相关的焦虑、躁狂、抑郁障碍，与可卡因、尼古丁、酒精和苯二氮平类物质戒断相关的影响，可用抗癫痫药物治疗和/或预防的疾病，如癫痫，包括创伤后癫痫，帕金森病，精神病，偏头痛等。

  公开号：

  US06395759B1

文献信息

• Substituted benzamide derivatives and pharmaceutical compositions containing them
  申请人：SmithKline Beecham p.l.c.

  公开号：US06395759B1

  公开（公告）日：2002-05-28

  Compounds of formula (I) and pharmaceutically acceptable salts thereof, where G is a methylene or ethylene linkage; R1 is hydrogen, C1-6alkylO—; R2 is hydrogen, halogen, CN, N3, trifluoromethyldiazirinyl, CF3, CF3O—, CF3S—, CF3CO—, C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkyl-C1-4alkyl-, C1-6alkylO—, C1-6alkylCO—, C3-6cycloalkylCO—, C3-6cycloalkyl-C1-4-alkylCO—, phenyl, phenoxy, benzyloxy, benzoyl and substituted benzoyl, phenyl-C1-4alkyl-, C1-6alkylSO2—, (C1-4alkyl)2NSO2— or (C1-4alkyl)NHSO2—; R3 is hydrogen, halogen, CN, N3, trifluoromethyldiazirinyl, C1-6alkylO—, C1-6alkylS—, C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkyl-C1-4alkyl-, C1-6alkenyl, C1-6alkynyl, CF3CO—, C1-6alkylCO—, C3-6cycloalkylCO—, C3-6cycloalkyl-C1-4alkylCO—, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C1-4alkyl-, or —NR5R6 where R5 is hydrogen or C1-4alkyl; and R6 is hydrogen, C1-4alkyl, —CHO, —CO2C1-4alkyl or —COC1-4alkyl; R4 is hydrogen, C1-6alkyl, C1-6alkenyl, or C1-6alkynyl, are useful in the prevention and treatment of anxiety, mania, depression disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, etc.

  公式（I）的化合物及其药学上可接受的盐，其中G为亚甲基或乙烯基链；R1为氢、C1-6烷基O-；R2为氢、卤素、CN、N3、三氟甲基二氮杂环基、CF3、CF3O-、CF3S-、CF3CO-、C1-6烷基、C3-6环烷基、C3-6环烷基-C1-4烷基、C1-6烷基O-、C1-6烷基CO-、C3-6环烷基CO-、C3-6环烷基-C1-4-烷基CO-、苯基、苯氧基、苄氧基、苯甲酰基和取代苯甲酰基、苯基-C1-4烷基-、C1-6烷基SO2-、(C1-4烷基)2NSO2-或(C1-4烷基)NHSO2-；R3为氢、卤素、CN、N3、三氟甲基二氮杂环基、C1-6烷基O-、C1-6烷基S-、C1-6烷基、C3-6环烷基、C3-6环烷基-C1-4烷基、C1-6烯基、C1-6炔基、CF3CO-、C1-6烷基CO-、C3-6环烷基CO-、C3-6环烷基-C1-4烷基CO-、苯基、苯氧基、苄氧基、苯甲酰基、苯基-C1-4烷基-或-NR5R6，其中R5为氢或C1-4烷基；R6为氢、C1-4烷基、-CHO、-CO2C1-4烷基或-COC1-4烷基；R4为氢、C1-6烷基、C1-6烯基或C1-6炔基，可用于预防和治疗与蛛网膜下腔出血或神经休克相关的焦虑、躁狂、抑郁障碍，与可卡因、尼古丁、酒精和苯二氮平类物质戒断相关的影响，可用抗癫痫药物治疗和/或预防的疾病，如癫痫，包括创伤后癫痫，帕金森病，精神病，偏头痛等。
• SUBSTITUTED BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0944598A2

  公开（公告）日：1999-09-29
• US6395759B1
  申请人：——

  公开号：US6395759B1

  公开（公告）日：2002-05-28
• [EN] SUBSTITUTED BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DERIVES DE BENZAMIDE SUBSTITUE ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：——

  公开号：WO1998024764A2

  公开（公告）日：1998-06-11

  [EN] Compounds of formula (I) and pharmaceutically acceptable salts thereof, where G is a methylene or ethylene linkage; R<1> is hydrogen, C1-6alkylO-; R<2> is hydrogen, halogen, CN, N3, trifluoromethyldiazirinyl, CF3, CF3O-, CF3S-, CF3CO-, C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkyl-C1-4alkyl-, C1-6alkylO-, C1-6alkylCO-, C3-6cycloalkylCO-, C3-6cycloalkyl-C1-4-alkylCO-, phenyl, phenoxy, benzyloxy, benzoyl and substituted benzoyl, phenyl-C1-4alkyl-, C1-6alkylSO2-, (C1-4alkyl)2NSO2- or (C1-4alkyl)NHSO2-; R<3> is hydrogen, halogen, CN, N3, trifluoromethyldiazirinyl, C1-6alkylO-, C1-6alkylS-, C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkyl-C1-4alkyl-, C1-6alkenyl, C1-6alkynyl, CF3CO-, C1-6alkylCO-, C3-6cycloalkylCO-, C3-6cycloalkyl-C1-4alkylCO-, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C1-4alkyl-, or -NR<5>R<6> where R<5> is hydrogen or C1-4alkyl; and R<6> is hydrogen, C1-4alkyl, -CHO, -CO2C1-4alkyl or -COC1-4alkyl; R<4> is hydrogen, C1-6alkyl, C1-6alkenyl, or C1-6alkynyl, are useful in the prevention and treatment of anxiety, mania, depression disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, etc.
  [FR] L'invention concerne de nouveaux composés de la formule (I) et des sels pharmaceutiquement acceptables desdits composés. Dans ladite formule, G est une liaison méthylène ou éthylène; R<1> est hydrogène, C1-6alkyleO-; R<2> est hydrogène, halogène, CN, N3, trifluorométhyldiazirinyle, CF3, CF3O-, CF3S-, CF3CO-, C1-6alkyle, C3-6cycloalkyle, C3-6cycloalkyle-C1-4alkyle-, C1-6alkyleO-, C1-6alkyleCO-, C3-6cycloalkyleCO-, C3-6cycloalkyle-C1-4-alkyleCO-, phényle, phénoxy, benzyloxy, benzoyle et benzoyle substitué, phényle-C1-4alkyle-, C1-6alkyleSO2-, (C1-4alkyle)2NSO2- ou (C1-4alkyle)NHSO2-; R<3> est hydrogène, halogène, CN, N3, trifluorométhyldiazirinyle, C1-6alkyleO-, C1-6alkyleS-, C1-6alkyle, C3-6cycloalkyle, C3-6cycloalkyle-C1-4alkyle-, C1-6alcényle, C1-6alkynyle, CF3CO-, C1-6alkyleCO-, C3-6cycloalkyleCO-, C3-6cycloalkyle-C1-4alkyleCO-, phényle, phénoxy, benzyloxy, benzoyle, phényle-C1-4alkyle- ou -NR<5>R<6>, R<5> étant hydrogène ou C1-4alkyle et R<6> étant hydrogène, C1-4alkyle, -CHO, -CO2C1-4alkyle ou -COC1-4alkyle; R<4> est hydrogène, C1-6alkyle, C1-6alcényle ou C1-6alkynyle. Lesdits composés sont utiles pour la prévention et le traitement d'affections telles que: anxiété, manie, affections dépressives liées à une hémorragie sous-arachnoïdienne ou choc nerveux, effets produits par le sevrage vis-à-vis de substances donnant lieu à des abus (cocaïne, nicotine, alcool ou benzodiazépines), maladies pouvant être traitées et/ou évitées à l'aide d'agents anti-convulsion, à savoir, par exemple, épilepsie (y compris l'épilepsie post-traumatique), maladie de Parkinson, psychose, migraine, etc.
• US6395759
  申请人：——

  公开号：——

  公开（公告）日：——